Which startups have raised the most funding in the longevity market?

Last updated: 7 September 2026

Download our beautiful pitch about the longevity market

market research pitch 2026 statistics longevity market

In our longevity market deck, you will find everything you need to understand the market

The longevity market now spans cellular rejuvenation, aging therapeutics, preventive diagnostics, wearables, biological-age testing, nutrition, and other technologies designed to extend healthy human lifespan.

To make this fast-moving market easier to follow, we maintain a ranking of the leading longevity startups based on the cumulative amount of funding each company has raised.

We update this list every month as new longevity funding rounds are announced, companies raise additional capital, and better historical fundraising information becomes available.

And if you want to better understand this new industry, you can download our pitch covering the longevity market.

A quick summary table

Metric Value
Most funded startup Altos Labs, $3.0B
Second most funded startup Oura, $1.7B
Largest funding round Altos Labs, $3.0B initial financing
Median funding $31M
Share of funding captured by the top 10 Approximately 67%
Median time since last round Approximately 23 months
Startups that raised funding in the last 12 months 29 confirmed
Longevity startups with at least $100M raised 23
Longevity funding captured by the top 3 Approximately 40%
Active longevity startups in the ranking 82 of 93
Chart illustrating yearly VC funding for longevity startups

This chart, featured in our longevity market deck, illustrates yearly VC funding for longevity startups

Top startups in the longevity market ranked by total funding raised

Here is an updated table that ranks the top startups in the longevity market based on the total amount of funding they have raised to date.

The table also includes the total number of funding rounds, the date and size of the latest round, the financing type (e.g. Series A, equity financing), key investors, the startup’s current status (active, IPO, acquired, or shut down), and a confidence score based on the data collected (we excluded startups with very low data confidence, to make sure everything is reliable).

If you're interested in knowing how much these startups are worth, you can check our list of the top startups in the longevity market ranked by valuation.

# Startup What They Do Total Raised ($) Total Rounds Last Round Date Last Round Amount ($) Last Round Type Key Investors Current Stage Confidence
1 Altos Labs Cellular rejuvenation therapeutics research $3.0B 1 January 2022 $3.0B Initial Financing / Series A ARCH Venture Partners, Jeff Bezos, Yuri Milner Active Strong
2 Oura Smart ring health monitoring $1.7B 6 October 2025 $900M Series E Fidelity, Iconiq, Atreides Active Full
3 Neko Health Preventive full-body health scanning $1.0B 3 July 2026 $700M Series C Lightspeed Venture Partners, O.G. Venture Partners, Atomico Active Full
4 BioSplice Therapeutics Alternative-splicing therapies degenerative diseases $770M 7 April 2021 $120M Series B / Equity Eventide, aMoon, Sands Capital Active Partial
5 NewLimit Epigenetic reprogramming longevity medicines $710M 4 June 2026 $435M Series C Founders Fund, Thrive Capital, Greenoaks Active Full
6 Insilico Medicine AI drug discovery for aging $524M 8 March 2025 $110M Series E Value Partners Group, Warburg Pincus, Prosperity7 Ventures IPO Full
7 BioAge Labs Aging biology therapeutics $516M 6 September 2024 $198M IPO Public investors, Sofinnova IPO Full
8 Calico Life Sciences Aging biology and therapeutics research $480M 2 2018 (month undisclosed) $240M Corporate Equity Alphabet Active Strong
9 Celularity Placental cellular and regenerative therapies $456M 10 2025 (month undisclosed) $5M Equity / preferred-stock financings Dragasac, Sorrento Therapeutics, Palantir IPO Partial
10 Human Longevity Precision health and longevity diagnostics $370M 4 August 2024 $40M Series B TVM Capital Healthcare, Panacea Venture, Emerging Technology Partners Active Strong
11 Function Health Preventive diagnostics and health intelligence $350M 5 November 2025 $298M Series B Redpoint Ventures, a16z, Battery Ventures Active Partial
12 Unity Biotechnology Therapies targeting diseases of aging $345M 8 November 2023 $4M Post-IPO Equity Existing warrant holders Shutdown Strong
13 Alzheon Oral therapies for Alzheimer’s disease $317M 7 February 2025 $126M Series E Extension Alerce Medical Technology Partners Active Partial
14 Life Biosciences Cellular rejuvenation therapies for aging $266M 6 April 2026 $80M Series D Undisclosed investors Active Strong
15 Juvenescence Longevity therapeutics and drug discovery $238M 4 May 2025 $76M Series B-1 M42 Active Strong
16 Nura Bio Neuroprotective aging medicines $215M 3 June 2026 $74M Series B The Column Group, Euclidean Capital, Sanofi Ventures Active Full
17 Viome Life Sciences Microbiome-driven personalized preventive health $200M 5 September 2024 $25M Series D Khosla Ventures, Bold Capital, Marc Benioff Active Partial
18 Retro Biosciences Cellular rejuvenation therapies $180M 3 May 2026 Undisclosed Series A Extension 4P Capital, Sam Altman Active Strong
19 SciNeuro Pharmaceuticals Neurodegenerative disease drug development $153M 2 December 2025 $53M Series B / Equity Lilly Asia Ventures, ARCH Venture Partners Active Full
20 Aeovian Pharmaceuticals Selective mTORC1 inhibitor therapeutics $142M 3 December 2025 $55M Series B Luma Group, CTI Life Sciences Fund, Foresite Capital Active Strong
21 Corsera Health Preventive cardiovascular RNAi and AI $130M 2 January 2026 $80M Series A Forbion, Population Health Partners, John Maraganore Active Partial
22 Nuritas AI-discovered bioactive peptide ingredients $112M 5 December 2024 $42M Series C M&G Investments, McWin Capital Partners, Grosvenor Food & AgTech Active Partial
23 Cambrian Bio Longevity biotech therapeutics $100M 2 2022 (month undisclosed) $80M Series A Apollo Health Ventures, KdT Ventures Active Partial
24 Fountain Life Preventive longevity diagnostics and clinics $98M 2 August 2025 $18M Series B EOS Ventures, B.K. Modi, Todd Wanek Active Partial
25 Loyal Dog longevity therapeutics $89M 4 November 2024 $45M Series B Bain Capital Ventures, First Round Capital Active Strong
26 L-Nutra Longevity and medical nutrition programs $87M 3 January 2026 $37M Series D Extension Mubadala, Brentwood Associates, Stéphane Bancel Active Partial
27 Rejuveron Life Sciences / Centenara Develops healthy-aging therapeutics portfolio $76M 2 September 2023 $75M Series B + Convertible Catalio Capital Management, Apeiron Investment Group, Mubadala Capital Active Partial
28 Timeline Mitopure-based cellular longevity products $75M 3 January 2024 $66M Series D BOLD / L'Oréal, Nestlé Health Science Active Partial
29 CohBar Mitochondrial-derived peptide therapeutics $70M 7 October 2021 $15M Public Offering Public-market investors Acquired Strong
30 Liom Non-invasive glucose monitoring wearable $67M 4 December 2025 $16M Series A Extension Red Bull Ventures, Marc Maurer, Melih Odemis Active Partial
31 resTORbio mTOR drugs for aging diseases $65M 2 November 2017 $40M Series B OrbiMed, Fidelity, Rock Springs Capital Acquired Full
32 Illimis Therapeutics Neurodegenerative and immune disease therapeutics $64M 3 July 2025 $42M Series B DSC Investment, Aju IB, IMM Investment Active Partial
33 Neurable Consumer brain-computer interface technology $63M 8 December 2025 $35M Series A Spectrum Moonshot Fund, Ascendo Venture Capital Active Partial
34 Elevian Regenerative medicines for stroke recovery $60M 3 September 2021 $40M Series A Prime Movers Lab, BOLD Capital, Leslie Ventures Active Strong
35 Blueprint Consumer longevity health optimization platform $60M 2 December 2025 Undisclosed Seed / Venture North Island Ventures Active Partial
36 Gordian Biotechnology In-vivo age-disease drug discovery $60M 4 November 2021 Undisclosed Series A Longevity Fund, Gigafund, Founders Fund Active Partial
37 Rubedo Life Sciences Drugs targeting pathological senescent cells $52M 2 April 2024 $40M Series A Khosla Ventures, Ahren Innovation Capital, Hevolution Foundation Active Strong
38 Neuraly Neurodegenerative disease drug development $47M 2 July 2018 $36M Series A D&D Pharmatech, Smilegate Investment, InterVest Active Strong
39 Arda Therapeutics Targeted cell depletion therapies $43M 1 October 2024 $43M Series A Andreessen Horowitz, Two Sigma Ventures, GV Active Strong
40 Alkahest Plasma-derived therapies for aging diseases $41M 2 March 2015 $38M Corporate Equity Grifols Acquired Full
41 Cellular Origins Automated cell therapy manufacturing $40M 1 December 2025 $40M Series A Johnson & Johnson Innovation, Highland Europe, BGF Active Full
42 LyGenesis Regrows organs using lymph nodes $40M 3 October 2024 $18M Series A-IV Undisclosed investors Active Partial
43 Tolerance Bio Thymus-based immune tolerance therapies $35M 2 June 2026 $15M Seed Extension / Early-stage Beyond Celiac Investments, BioAdvance Active Strong
44 Jocasta Neuroscience Klotho therapeutics for cognitive decline $35M 1 August 2025 $35M Series A True Ventures, Moore Strategic Ventures, SC8 Investments Active Full
45 Gero AI discovers aging drug targets $34M 4 June 2026 $17M Series B Chugai Pharmaceutical, Melnichek Investments Active Strong
46 Amplifier Therapeutics Develops AMPK activator therapeutics $33M 1 October 2023 $33M Series A RA Capital Management, Future Ventures, Cambrian Bio Active Full
47 MindImmune Therapeutics Neuroinflammation therapies for brain diseases $31M 3 November 2025 $11M Series A Extension Dolby Family Ventures, Gates Frontier, Pfizer Ventures Active Strong
48 Rejuvenate Bio Gene therapies for age-related diseases $30M 2 June 2026 $20M Venture / Private Equity VCapital, Merck Animal Health, Digitalis Ventures Active Partial
49 Turn Biotechnologies Epigenetic cellular rejuvenation therapies $29M 4 May 2024 Undisclosed Venture Methuselah Fund Active Partial
50 Repair Biotechnologies Reverses cholesterol-driven age-related disease $27M 8 November 2025 $5M Venture Equity Healthspan Capital, LongevityTech.Fund, Bioverge Active Strong
51 Elysium Health Science-based longevity health products $26M 3 December 2016 $20M Series B General Catalyst, Breyer Capital, Morningside Ventures Active Partial
52 Cyclarity Therapeutics Anti-aging cholesterol therapies $24M 4 December 2024 $6M Series A Tranche Ki Tua Fund, Bill Liao Active Strong
53 Oisín Biotechnologies Genetic medicines targeting aging mechanisms $22M 5 July 2024 $15M Series A AbbVie Ventures Active Partial
54 Junevity siRNA cellular reprogramming therapeutics $20M 2 December 2025 $10M Seed Extension Goldcrest Capital, Godfrey Capital Active Full
55 Shift Bioscience AI cellular rejuvenation platform $18M 2 October 2024 $16M Seed BGF, F-Prime Capital, Kindred Capital Active Strong
56 Deciduous Therapeutics Immune therapies targeting senescent cells $17M 2 December 2022 $10M Seed 8VC, CRV, Longevity investors Active Strong
57 Longevica Longevity therapeutics and lifespan research $16M 2 November 2021 $3M Venture Round Xploration Capital, Alexander Chikunov Active Partial
58 Generation Lab Biological age diagnostic platform $15M 2 October 2025 $11M Seed Accel, Samsung Next, Aoki Labs Active Strong
59 Cirrus Therapeutics Ocular aging gene therapies $15M 2 August 2026 $4M Seed Extension Cedars Sinai IPC, ClavystBio, Polaris Partners Active Full
60 Modulo Bio Neuroimmune drugs for neurodegeneration $14M 2 December 2024 $6M Seed Initialized Capital Active Strong
61 Edifice Health Measures and manages chronic inflammation $14M 2 April 2021 $12M Series A Leaps by Bayer, Paladin Capital, Ahren Active Full
62 GlycanAge Glycan-based biological age diagnostics $13M 3 December 2025 $9M Series A LAUNCHub Ventures, Guinness Ventures, BrightCap Ventures Active Partial
63 Radar Therapeutics Programmable RNA-sensing precision medicines $13M 1 May 2024 $13M Seed NFX Bio, Eli Lilly, Biovision Ventures Active Strong
64 Morphoceuticals Bioelectric tissue and organ regeneration $13M 3 October 2024 $4M Seed Ferocity Capital Active Partial
65 Amphix Bio Peptide therapies for neurological diseases $13M 1 December 2025 $13M Seed Undisclosed investor syndicate Active Strong
66 Circulate Health Therapeutic plasma exchange longevity clinics $12M 2 December 2025 Undisclosed Strategic / Early VC Scrum Ventures Acquired Strong
67 Acorn Biolabs Banks cells for regenerative treatments $12M 3 May 2024 $8M Series A Merz Aesthetics, TELUS Global Ventures, MDE Investments Active Full
68 Epiterna Drugs that slow biological aging $11M 1 August 2023 $11M Seed / Early VC Prima Materia Active Full
69 Rejuvenation Technologies Telomere-extending mRNA longevity therapeutics $11M 2 September 2023 $11M Seed Khosla Ventures, Shanda Ventures, Asymmetry Ventures Active Strong
70 Minovia Therapeutics Mitochondrial augmentation cell therapies $10M 2 January 2025 Undisclosed Seed / Venture 4T Ventures Active Partial
71 Tally Health Consumer epigenetic biological-age testing $10M 1 April 2023 $10M Seed Forerunner Ventures, L Catterton, G9 Ventures Acquired Full
72 AgelessRx Longevity telehealth and clinical research $9M 3 March 2026 $5M Equity / Venture Pareto Holdings, 1/0 Capital, Rankin Ventures Active Partial
73 clock.bio Cellular rejuvenation platform $9M 2 October 2024 $5M Seed LocalGlobe, BlueYard Capital, Onsight Ventures Active Strong
74 SENISCA RNA therapies reverse cellular senescence $9M 3 March 2024 $5M Seed Emerging Longevity Ventures, QantX, R42 Group Active Strong
75 Grey Matter Neurosciences Neuroscience aging therapies $8M 1 2023 (month undisclosed) $8M Seed Apollo Health Ventures, Northpond Ventures Active Partial
76 MitoRx Therapeutics Mitochondrial longevity drugs $7M 1 November 2025 $7M Pre-Series A Oshen Holdings SA, Fink Family Office Active Strong
77 Biopeak Personalized preventive longevity healthcare $7M 3 January 2026 $3M Seed Extension NKSquared Active Strong
78 Thymmune Therapeutics Regenerative thymus cell therapies $7M 1 March 2023 $7M Seed Pillar VC, NYBC Ventures, John Maraganore Acquired Strong
79 Cyclana Bio Tissue-based endometriosis drug discovery $7M 1 October 2025 $7M Pre-Seed NFX, Eka VC, Cocoa VC Active Full
80 NaNotics Nanomedicines remove pathological blood targets $6M 2 October 2023 $3M Series A LifeSpan Vision Ventures, Lauder Partners Active Low
81 Vincere Biosciences Mitophagy therapeutics for neurodegeneration $6M 3 2025 (month undisclosed) Undisclosed Series A / Corporate Minority HanAll Biopharma, Daewoong Pharmaceutical, Beiersdorf Active Low
82 Vasa Therapeutics Therapies targeting cardiovascular aging $6M 2 January 2024 $6M Series Seed Orphinic Scientific, NuFund Venture Group, SeedFolio Active Partial
83 Genflow Biosciences Gene therapies for aging $6M 3 2024 (month undisclosed) $1M Equity Placing Existing shareholders Active Strong
84 Biolytica Personalized health-data longevity platform $6M 2 May 2023 $6M Seed Maximon Active Partial
85 Leucadia Therapeutics Restores cerebrospinal-fluid drainage Alzheimer’s $5M 2 July 2019 Undisclosed Seed Methuselah Foundation, Methuselah Fund Active Low
86 Tomorrow Bio Human cryopreservation services $5M 1 2022 (month undisclosed) $5M Seed Apeiron Investment Group, Deep Knowledge Group Active Low
87 Everlab Preventive longevity diagnostics $4M 1 2024 (month undisclosed) $4M Seed Blackbird Ventures, Rampersand Active Low
88 NOVOS Science-backed consumer longevity products $4M 2 March 2026 Undisclosed Strategic VC Unilever Ventures Active Partial
89 Mito Health AI-powered personalized preventive healthcare $4M 2 March 2025 $2M Seed Y Combinator, Capital X, XA Network Active Strong
90 Bionic Health AI-powered preventive longevity care $3M 2 July 2024 Undisclosed Seed Extension TowerView Ventures, Alumni Ventures, Triangle Tweener Fund Acquired Partial
91 Matter Bio Aging biotechnology platform $3M 1 2024 (month undisclosed) $3M Seed Longevity angels Active Low
92 ImmuneAGE Bio Rejuvenates aging immune stem cells $2M 2 July 2024 $2M Seed 1517 Fund, Emerging Longevity Ventures, Healthspan Capital Active Partial
93 NADMED NAD metabolism diagnostics $2M 1 2022 (month undisclosed) $2M Seed Finnish health-tech investors Active Partial
Market map chart showing top companies and startups in the longevity market

This market map, featured in our longevity market deck, highlights top companies and startups in the longevity market

Key funding trends in the longevity market

Insights

  • Funding in the longevity market is highly concentrated. The ten largest companies have raised approximately $9.5B, around 67% of the roughly $14.2B represented across the 93 startups in this ranking.
  • The typical longevity startup is much smaller than the market leaders suggest. Median cumulative funding is only $31M, while the average is roughly $152M because a small number of billion-dollar companies pull the mean sharply higher.
  • Only 23 longevity startups have raised at least $100M, yet those companies account for approximately $12.3B, or almost 87% of all capital represented in the ranking.
  • Recent fundraising remains active across the longevity market. At least 29 companies completed a documented funding round during the 12 months ending September 2026, including Neko Health, NewLimit, Nura Bio and Life Biosciences.
  • Large later rounds can transform a longevity company’s capital base quickly. Oura's $900M Series E represents roughly 53% of lifetime funding, while Neko Health's $700M Series C represents about 70%.
  • Capital concentration does not belong only to therapeutics. Oura and Neko Health have raised roughly $2.7B combined, showing how consumer monitoring and preventive diagnostics can compete with drug-development platforms for institutional capital.
  • NewLimit and Life Biosciences illustrate very different funding paths within cellular rejuvenation. NewLimit reached $710M across four rounds, while Life Biosciences accumulated $266M across six rounds.
  • Unity Biotechnology is an important reminder for longevity investors. Approximately $345M of cumulative funding still preceded shutdown, showing that substantial capitalization cannot remove clinical, biological, or development risk.
Google Trends chart showing rising interest in longevity

As this slide shows, and as featured in our longevity market deck, online search interest in longevity has been steadily increasing

A few word about our methodology

As you can see, we built a database that ranks startups in the longevity market based on their total cumulative fundraising. To create this ranking, we reviewed many sources and cross-checked information across multiple places.

Whenever possible, we prioritized official company communications, since they are the most reliable source for longevity funding amounts. When those were not available, we relied on reputable industry sources such as TechCrunch, Crunchbase, Financial Times or Forbes (to name a few).

We excluded random blogs, unverified websites, and any sources that could not be validated.

When longevity funding rounds were announced in other currencies such as euros, Swiss francs, Singapore dollars, Australian dollars, or rupees, we converted them into approximate USD equivalents for consistency.

Sometimes different sources report slightly different numbers, or the exact round size is not fully disclosed. In those cases, we flag the uncertainty and assign a confidence label to each longevity startup, visible in the last column.

Here is what they mean.

Full confidence: The company’s equity fundraising history can be reconstructed completely from public sources. The rounds, dates, amounts, and key investors are clearly identified, with no meaningful gaps.

Strong confidence: The fundraising history is largely complete and reliable. There may be a small missing detail, such as incomplete investor information or a minor round with limited data, but the overall record is clear.

Partial confidence: The main fundraising rounds can be identified, but the record is incomplete or somewhat mixed. Some rounds may be missing or certain funding events may be difficult to separate clearly.

Low confidence: Public information is too limited, inconsistent, or ambiguous to reliably reconstruct the company’s equity fundraising history.

When the confidence level is too low, we take a conservative approach and exclude the company from the ranking. We don’t want to include data that cannot be reliably verified.

This reflects how we conduct all our research, including the work behind our report covering the longevity market.

In a world where LLMs hallucinate and unreliable information is everywhere, our goal is simple: provide data you can trust.

If you want the full detail on a specific calculation, feel free to contact us and we will gladly explain.

Finally, know that we update the dataset once per month, so come back here if you need fresh information.

Chart showing Function Health’s strategy in the longevity market

This chart, featured in our longevity market deck, looks at Function Health’s strategy in longevity

Who is the author of this content?

NEW MARKET PITCH TEAM

We track new markets so founders and investors can move faster

We build living “market pitch” documents for emerging markets: from AI to synthetic biology and new proteins. Instead of digging through outdated PDFs, random blog posts, and hallucinated LLM answers, our clients get a clean, visual, always-updated view of what’s really happening. We map the key players, deals, regulations, metrics and signals that matter so you can decide faster whether a market is worth your time. Want to know more? Check out our about page. You can also follow us on Instagram or on Facebook.

How we created this content 🔎📝

At New Market Pitch, we kept seeing the same problem: when you look at a new market, the data is either missing, paywalled, or buried in 300-page reports that feel like they were written in the 80s. On the other side, LLMs and random blog posts give you confident answers with no sources, and sometimes they just make things up. That’s not good enough when you’re about to invest real money or launch a company.

So we decided to fix the experience. For each market we cover, we build a structured database and update it on a regular basis. We track funding rounds, fund memos, M&A moves, partnerships, new products, policy changes, and the real activity of startups and incumbents. Then we turn all of that into a clear “market pitch” that shows where the opportunities are and how people actually win in that space.

Every key data point is checked, sourced, and put back into context by our team. That’s how we can give you both speed and reliability: fast coverage of new markets, without the usual guesswork.